in ,

Strategies to reduce the risks of mRNA drug and vaccine toxicity

Strategies to reduce the risks of mRNA drug and vaccine toxicity

Abstract

mRNA formulated with lipid nanoparticles is a transformative technology that has enabled the rapid development and administration of billions of coronavirus disease 2019 (COVID-19) vaccine doses worldwide. However, avoiding unacceptable toxicity with mRNA drugs and vaccines presents challenges. Lipid nanoparticle structural components, production methods, route of administration and proteins produced from complexed mRNAs all present toxicity concerns. Here, we discuss these concerns, specifically how cell tropism and tissue distribution of mRNA and lipid nanoparticles can lead to toxicity, and their possible reactogenicity. We focus on adverse events from mRNA applications for protein replacement and gene editing therapies as well as vaccines, tracing common biochemical and cellular pathways. The potential and limitations of existing models and tools used to screen for on-target efficacy and de-risk off-target toxicity, including in vivo and next-generation in vitro models, are also discussed.

What do you think?

Written by colinnew

Leave a Reply

Your email address will not be published. Required fields are marked *

Von der Leyen withdraws contentious pesticide law amid right-wing backlash and farmer protests

Von der Leyen withdraws contentious pesticide law amid right-wing backlash and farmer protests

The Daily Brief | Trudeau’s office sent invite to Nazi veteran

The Daily Brief | Trudeau’s office sent invite to Nazi veteran